Shares of Divis Laboratories were trading at Rs 6,209 in Wednesday's session, marking a 3.12% decrease. The stock experienced a notable downturn amid high volume, volume surge, and unusual volume, positioning it among the top losers on the Nifty Next 50.
Financial Snapshot:Divis Laboratories has demonstrated consistent financial performance over the recent years. Here's a summary of the company's key financial metrics:
| Financial Year | Revenue (Rs. Crore) | Net Profit (Rs. Crore) | EPS (Rs.) | BVPS (Rs.) | ROE (%) | Debt to Equity |
|---|---|---|---|---|---|---|
| Mar 2025 | 9,360.00 | 2,191.00 | 82.53 | 564.87 | 14.63 | 0.00 |
| Mar 2024 | 7,845.00 | 1,600.00 | 60.27 | 512.11 | 11.78 | 0.00 |
| Mar 2023 | 7,767.51 | 1,823.38 | 68.69 | 480.96 | 14.28 | 0.00 |
| Mar 2022 | 8,959.83 | 2,960.45 | 111.52 | 441.82 | 25.24 | 0.00 |
| Mar 2021 | 6,969.40 | 1,984.29 | 74.75 | 350.15 | 21.34 | 0.00 |
In fiscal year 2025, Divis Laboratories reported a revenue of Rs 9,360.00 Crore, marking an increase compared to Rs 7,845.00 Crore in fiscal year 2024. The net profit for the same period was Rs 2,191.00 Crore, up from Rs 1,600.00 Crore. EPS also increased to Rs 82.53 from Rs 60.27.
Income Statement (Yearly):| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Sales | 9,360 | 7,845 | 7,767 | 8,959 | 6,969 |
| Other Income | 352 | 339 | 344 | 113 | 62 |
| Total Income | 9,712 | 8,184 | 8,112 | 9,073 | 7,031 |
| Total Expenditure | 6,794 | 6,018 | 5,742 | 5,389 | 4,365 |
| EBIT | 2,918 | 2,166 | 2,369 | 3,684 | 2,666 |
| Interest | 2 | 3 | 0 | 0 | 0 |
| Tax | 725 | 563 | 545 | 723 | 681 |
| Net Profit | 2,191 | 1,600 | 1,823 | 2,960 | 1,984 |
The sales for the year ending March 2025 stood at Rs 9,360 Crore, which is an increase compared to the sales of Rs 7,845 Crore in March 2024. The company's total expenditure increased from Rs 6,018 Crore to Rs 6,794 Crore during the same period.
Income Statement (Quarterly):| Particulars | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|
| Sales | 2,585 | 2,319 | 2,338 | 2,118 | 2,303 |
| Other Income | 86 | 82 | 106 | 79 | 79 |
| Total Income | 2,671 | 2,401 | 2,444 | 2,197 | 2,382 |
| Total Expenditure | 1,806 | 1,675 | 1,721 | 1,593 | 1,667 |
| EBIT | 865 | 726 | 723 | 604 | 715 |
| Interest | 1 | 0 | 1 | 0 | 2 |
| Tax | 202 | 137 | 212 | 174 | 175 |
| Net Profit | 662 | 589 | 510 | 430 | 538 |
The revenue for the quarter-ending March 2025 was Rs 2,585 Crore, up from Rs 2,319 Crore in the quarter-ending December 2024. Similarly, the net profit increased from Rs 589 Crore to Rs 662 Crore during the same period.
Cash Flow:| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Operating Activities | 1,653 | 1,261 | 2,459 | 1,911 | 1,946 |
| Investing Activities | -804 | -269 | -2,707 | -2,194 | 75 |
| Financing Activities | -799 | -799 | -797 | -532 | -34 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 50 | 193 | -1,045 | -815 | 1,987 |
Cash flow from operating activities for the year ending March 2025 was Rs 1,653 Crore compared to Rs 1,261 Crore for the year ending March 2024. Investing activities showed an outflow of Rs -804 Crore, while financing activities also resulted in an outflow of Rs -799 Crore.
Balance Sheet:| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Share Capital | 53 | 53 | 53 | 53 | 53 |
| Reserves & Surplus | 14,916 | 13,518 | 12,714 | 11,675 | 9,241 |
| Current Liabilities | 1,452 | 1,278 | 1,101 | 1,195 | 1,112 |
| Other Liabilities | 511 | 621 | 570 | 450 | 367 |
| Total Liabilities | 16,932 | 15,470 | 14,438 | 13,374 | 10,774 |
| Fixed Assets | 6,464 | 5,517 | 4,934 | 4,794 | 4,414 |
| Current Assets | 10,081 | 9,675 | 9,311 | 8,351 | 6,174 |
| Other Assets | 387 | 278 | 192 | 228 | 184 |
| Total Assets | 16,932 | 15,470 | 14,438 | 13,374 | 10,774 |
| Contingent Liabilities | 1,841 | 1,432 | 736 | 1,259 | 1,107 |
The total liabilities for the year ending March 2025 were Rs 16,932 Crore, compared to Rs 15,470 Crore for the year ending March 2024. Fixed assets increased from Rs 5,517 Crore to Rs 6,464 Crore during the same period.
Key Financial Ratios:| Ratio | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 82.53 | 60.27 | 68.69 | 111.52 | 74.75 |
| Diluted EPS (Rs.) | 82.53 | 60.27 | 68.69 | 111.52 | 74.75 |
| Book Value / Share (Rs.) | 564.87 | 512.11 | 480.96 | 441.82 | 350.15 |
| Dividend/Share (Rs.) | 30.00 | 30.00 | 30.00 | 30.00 | 20.00 |
| Face Value | 2 | 2 | 2 | 2 | 2 |
| Gross Profit Margin (%) | 35.47 | 32.42 | 34.92 | 44.59 | 41.93 |
| Operating Margin (%) | 31.17 | 27.60 | 30.50 | 41.12 | 38.26 |
| Net Profit Margin (%) | 23.40 | 20.39 | 23.47 | 33.04 | 28.47 |
| Return on Equity (%) | 14.63 | 11.78 | 14.28 | 25.24 | 21.34 |
| ROCE (%) | 18.85 | 15.26 | 17.76 | 30.25 | 27.60 |
| Return On Assets (%) | 12.93 | 10.34 | 12.62 | 22.13 | 18.41 |
| Current Ratio (X) | 6.94 | 7.57 | 8.46 | 6.99 | 5.55 |
| Quick Ratio (X) | 4.71 | 5.08 | 5.73 | 4.62 | 3.62 |
| Debt to Equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratios (X) | 1,660.00 | 848.00 | 4,048.48 | 4,994.76 | 3,065.41 |
| Asset Turnover Ratio (%) | 0.58 | 0.52 | 0.56 | 0.74 | 64.68 |
| Inventory Turnover Ratio (X) | 2.92 | 1.05 | 1.03 | 1.44 | 3.25 |
| 3 Yr CAGR Sales (%) | 2.21 | 6.10 | 20.00 | 34.59 | 33.83 |
| 3 Yr CAGR Net Profit (%) | -13.97 | -10.20 | 15.09 | 47.94 | 50.42 |
| P/E (x) | 69.98 | 57.16 | 41.10 | 39.47 | 48.47 |
| P/B (x) | 10.22 | 6.71 | 5.88 | 9.97 | 10.37 |
| EV/EBITDA (x) | 44.96 | 34.24 | 26.10 | 28.55 | 32.23 |
| P/S (x) | 16.34 | 11.61 | 9.66 | 13.05 | 13.83 |
The P/E ratio for Divis Laboratories as of March 2025 is 69.98, and the P/B ratio is 10.22. The company's debt-to-equity ratio remains at 0.00, indicating a debt-free status.
Divis Laboratories has scheduled a board meeting on August 6, 2025, to consider and approve the unaudited financial results for the quarter ended June 30, 2025. The company also announced the schedule for the Q1FY2026 earnings call.
In terms of dividends, the company has consistently distributed final dividends. Most recently, a final dividend of Rs 30 per share (1500%) was announced on May 19, 2025, with an effective date of July 25, 2025. Further, the company had announced a final dividend of Rs 30 per share on May 27, 2024, with an effective date of August 2, 2024.
Additionally, the company has a history of bonus issues, with the last bonus being announced on August 8, 2015, in the ratio of 1:1. A stock split was announced on May 23, 2007, with the old face value of Rs 10 being split into a new face value of Rs 2; the ex-split date was August 3, 2007.
The stock's movement reflects a very bearish sentiment, according to a Moneycontrol analysis as of July 31, 2025.
With the stock currently trading at Rs 6,209, Divis Laboratories has experienced a notable downturn amid high trading volumes and bearish market sentiment.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
